WILLIAM WALSH: Open Payments
NPI 1730374604 · OGDEN, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,583 in 36 payments from 18 companies in 2025. Trend: 2023 $235 · 2024 $1,191 · 2025 $1,583
Food & beverage: $1,484Education: $99
| Company | Payments | Amount |
|---|---|---|
| Indivior Inc. | 10 | $245 |
| Edwards Lifesciences Corporation | 1 | $202 |
| Corcept Therapeutics | 2 | $152 |
| AstraZeneca Pharmaceuticals LP | 2 | $138 |
| Phathom Pharmaceuticals, Inc. | 1 | $125 |
| Novo Nordisk Inc | 1 | $122 |
| Astellas Pharma US Inc | 2 | $118 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $108 |
| GlaxoSmithKline, LLC. | 2 | $107 |
| ABBVIE INC. | 3 | $55 |
Products named: SUBLOCADE, SAPIEN 3 Ultra RESILIA, Korlym, VOQUEZNA, Ozempic, CAPLYTA, AREXVY, VRAYLAR.
Industry payments across UT — which companies pay providers there.
